The use of drug treatments for Alzheimer's disease in France: Analysis of practices based on the National Bank of Alzheimer's disease;Usage des médicaments anti-Alzheimer en France: Une analyse des pratiques à partir de la Banque Nationale de donnees Alzheimer (BNA)

Revue de Geriatrie

Volumn 36, Issue 8, 2011, Pages 557-565

  Tifratene, Karim ^a   Le Duff, Franck ^a   Pradier, Christian ^a   Quetel, Julien ^a,b   Robert, Philippe ^b  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^b UNIVERSITY HOSPITAL OF NICE   (France)

Author keywords

Alzheimer's disease; Cholinergic inhibitors; National Bank of Alzheimer's disease; NMDA receptors inhibitors; Practice analysis

Indexed keywords

EID: 81255150711     PISSN: 03977927     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Alzheimer's Disease International. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005; 366: 2112-2117. (Pubitemid 41797645)
2. Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, et al. Prevalence of dementia and major subtypes in Europe: A collaborative study of population based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000; 54(Suppl 5): S4-9. (Pubitemid 30390598)
3. Ramaroson H, Helmer C, Barberger-Gateau P, Letenneur L, Dartigues JF. Prevalence de la demence et de la maladie d'Alzheimer chez les personnes de 75 ans et plus : donnees reactualisees de la cohorte Paquid. Rev Neurol. 2003 ; 159:405-411. (Pubitemid 36548160)
4. Institut national de la sante et de la recherche medicate (lnserm). Maladie d'Alzheimer - enjeux scientifiques, medicaux et sodetaux. Editions lnserm. Collection Expertise collective, 656 pages, ist.inserm.fr/basisrapports/ alzheimer.html
5. Jonsson L, Wimo A. The cost of dementia in Europe: a review of the evidence, and methodological considerations. Pharmacoeconomics. 2009 ; 27:391-403.
6. C. Gallez. Rapport sur la maladie d'Alzheimer et les maladies apparentees, Office Parlementaire d'evaluation des politiques de sante. 2005.
7. Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst. 2006 ; 25.CD001747.
8. Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE. Rivastigmine for Alzheimer's disease. Cochrane Database Syst. Rev. 2009 ; 15CD001191.
9. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst. Rev. 2006 ; 25:CD001190.
10. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006, 2: CD003154.
11. Cummings JL. Alzheimer's Disease. N Engl J Med. 2004; 351:56-67.
12. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, Van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ. 2005 ;331:321-327.
13. Haute Autorite de Sante. Diagnostic et prise en charge de la maladie d'Alzheimer et des maladies apparentees. Recommandations professionnelles. Mars 2008
14. http://www.plan-alzheimer.gouv.fr/IMG/pdf/plan-alzheimer-2008- 2012.pdf
15. Le Duff F, Duport N, Gonfrier S, Lafay P, Texier N, Schiick S, et al et les centres participants. Plan national Alzheimer 2008-2012 - Mesure 34. Mise en place du recueil epidemiologique national et premieres tendances. La Revue de Gériatrie. 2010 ; 35-575-582.
16. Woolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J. Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines. BMJ. 1999 ; 318:527-530. (Pubitemid 29189000)
17. Donnees sur l'utilisation et la prescription en France des medicaments indiques dans la maladie d'Alzheimer. Annexe du dossier de re-evaluation des medicaments indiques dans la maladie d'Alzheimer. 2007. www.has-sante.fr
18. Pariente A, Helmer C, Merliere Y, Moore N, Fourrier-Reglat A, Dartigues J-F. Prevalence of cholinesterase inhibitors in subjects with dementia in Europe. Pharmacoepidemiology and Drug Safety. 2008 ; 17: 655-660.
19. Vidal JS, Lacombe JM, Dartigues JF, Pasquier F, Robert P, Tzourio C, et al. Memantine therapy for Alzheimer disease in real-world practice: an observational study in a large representative sample of French patients. Alzheimer Dis Assoc Disord. 2008 ; 22:125-130.
20. Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord. 2008 ; 22:209-221.
21. Lopez OL, Becker JT, Waned AS, Saxton J, Sweet RA, Wolk DA, et al. Long-term eff ects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry. 2009 ; 80:600-607.
22. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. Donepezil MSAD Study Investigators Group. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology. 2001 ; 57:613-620. (Pubitemid 32782987)
23. Epstein NU, Saykin AJ, Risacher SL, Gao S, Farlow MR. Alzheimer's Disease Neuroimaging Initiative (ADNI). Differences in medication use in the Alzheimer's disease neuroimaging initiative: analysis of baseline characteristics. Drugs Aging. 2010 ; 27.677-686.
24. Bowie P, Branton T, Holmes J. Should the Mini Mental State Examination be used to monitor dementia treatments? Lancet. 2000 ; 355:314-315. (Pubitemid 30068533)
25. Gauthier S, Loft H, Cummings J. Improvement in behavioral symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry. 2008 ; 23: 537-545. (Pubitemid 351722115)
26. Rockwood K, Fay S, Song X, MacKnight C, Gorman M. Video- Imaging Synthesis of Treating Alzheimer's Disease (VISTA) Investigators. Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial. CMAJ. 2006 ; 174: 1099-1005.
27. Ballard C, Gauthier S, Corbert A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet. 2011 ; 377:1019-1031.
28. Ballard C, Howard R. Neuroleptic drugs in dementia: benefits and harm. Nat Rev Neurosci. 2006 ; 7: 492-500. (Pubitemid 44012289)
29. Ballard C, Hanney ML, Theodoulou M, et al. DART-AD investigators. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol. 2009 ; 8:151-157.
30. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. Review of NICE technology appraisal guidance 111. NICE technology appraisal guidance 217. March 2011.
31. Waldemar G, Dubois B, Emre M, Georges J, McKeith IG, Rossor M, et al. Recommendations for the diagnosis and management of Alzheimer'sdisease and other disorders associated with dementia: EFNS guideline. European Journal of Neurology. 2007 ; 14: e1-e26. (Pubitemid 46088015)
32. Radley DC, Finkelstein SN, Stafford RS. MDOfHabel Prescribing Among Office-Based Physicians. Arch Intern Med. 2006 ; 166:1021-1026.